Gold Investment Management Ltd. Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Gold Investment Management Ltd. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,389 shares of the company’s stock after acquiring an additional 168 shares during the quarter. Gold Investment Management Ltd.’s holdings in Johnson & Johnson were worth $2,515,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of JNJ. Creative Financial Designs Inc. ADV boosted its stake in shares of Johnson & Johnson by 7.6% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 9,509 shares of the company’s stock valued at $1,375,000 after purchasing an additional 668 shares during the period. IMG Wealth Management Inc. bought a new position in Johnson & Johnson in the 4th quarter worth about $483,000. Signature Wealth Management Group increased its position in shares of Johnson & Johnson by 4.9% during the fourth quarter. Signature Wealth Management Group now owns 27,864 shares of the company’s stock worth $4,030,000 after acquiring an additional 1,295 shares during the period. SlateStone Wealth LLC raised its stake in shares of Johnson & Johnson by 2.4% during the fourth quarter. SlateStone Wealth LLC now owns 69,864 shares of the company’s stock valued at $10,104,000 after acquiring an additional 1,637 shares in the last quarter. Finally, First National Advisers LLC boosted its holdings in shares of Johnson & Johnson by 2.8% in the fourth quarter. First National Advisers LLC now owns 19,064 shares of the company’s stock valued at $2,757,000 after purchasing an additional 527 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JNJ shares. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.0 %

JNJ stock opened at $162.94 on Monday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a market capitalization of $392.29 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The firm has a 50 day moving average of $154.98 and a 200 day moving average of $156.27.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.29 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.